Search the Newsreel

Quoin Q2 Loss Hits $5.37 Million as FDA Clears Peeling Skin IND

Quoin Pharmaceuticals Ltd. (QNRX) reported a net loss of $5.37 million for the second quarter of 2026, an increase from $3.70 million in the prior year. Despite this, the company's cash position is expected to fund operations into 2027. The FDA also conditionally approved …

Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition

Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership

Southpoint-related entities and individual John S. Clark have filed an amended Schedule 13G/A for Fennec Pharmaceuticals Inc. (FENC), indicating that they now beneficially own 0 Common Shares, representing 0% of the class. This filing signifies that their ownership is 5 percent or less, with …

Profound Medical CFO Steps Down; Controller Takes Interim Role

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced a management change, with Matthew Sobczyk, formerly Corporate Controller, promoted to Interim Chief Financial Officer. He succeeds Rashed Dewan, who has stepped down but will remain on a short-term consulting contract to ensure a smooth transition. …

Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026

Galmed Pharmaceuticals (GLMD) has announced a 1-for-8 reverse share split, consolidating its ordinary shares, with post-split trading expected to begin on August 19, 2026, on the Nasdaq Capital Market. This action will reduce the number of outstanding shares from 8,332,518 to approximately 1,041,565 and …

Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity

Amneal Pharmaceuticals director John Kiely reported selling 50,000 shares of Class A Common Stock at a weighted average price of $17.64 per share on August 13, 2026. Additionally, he made a charitable donation of 10,000 shares of Class A Common Stock to a donor-advised …

Wasserstein group (CLMT) discloses 4.6% Calumet Inc. ownership in Schedule 13G/A

Wasserstein Management L.P. and its affiliated entities have reported a beneficial ownership of 4.6% in Calumet Inc. (CLMT) common stock, as detailed in an amended Schedule 13G filing on June 30, 2026. This stake amounts to 3,964,893 shares out of 87,147,147 total shares outstanding. …

Intuitive Surgical Inc. stock underperforms Friday when compared to competitors

Intuitive Surgical Inc. (ISRG) shares fell 1.68% to $394.51 on Friday, underperforming the broader market as the S&P 500 and Dow Jones also experienced slight declines. The company's stock closed 34.67% below its 52-week high, which was set on January 7th. This report highlights …

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing …

Renatus Tactical (RTAC) posts Q2 update with $252M in trust and going concern risk

Renatus Tactical Acquisition Corp I Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Local Bounti Corp (NYSE: LOCL) Share Price, LOCL Stock News, LOCL Share Price & Updates

The Calmer Co International Ltd (CCO) Stock Forecast & Analyst Ratings

North Reef Capital discloses 5.5% i3 Verticals (IIIV) ownership in Schedule 13G

North Reef Capital Management LP, along with North Reef Capital Management GP LLC and James Hanna, III, has disclosed a beneficial ownership of 1,075,000 shares of i3 Verticals, Inc. Class A common stock, representing 5.50% of the class. This disclosure was made in a …

Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake

Citadel-affiliated entities, including Kenneth Griffin, have disclosed a beneficial ownership of 206,354 shares in Corbus Pharmaceuticals Holdings, Inc. This represents a 1.1% stake in the company, based on 18,527,795 shares outstanding as of May 8, 2026. The filing indicates shared voting and dispositive power …

PMV Pharmaceuticals Releases Q2 2026 Financial Results

PMV Pharmaceuticals reported a narrower loss for Q2 2026, with a loss of $0.34 per share compared to $0.41 in the prior year, marking a 17.1% improvement. The precision oncology company recorded a net loss of $18.1 million as it continues to invest in …

Why Eton Pharmaceuticals Is Top of the Class Today

Key Points Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.10 stocks we like better than Eton Pharmaceuticals › Eton Pharmaceuticals (NASDAQ: ETON) stock soared 41.9% through 2:15 …

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

West Pharmaceutical Services (WST) stock has seen a significant rally, surging 38.1% since the end of March, driven by strong organic revenue growth and increased adjusted EPS. The company benefits from high demand for its proprietary products, particularly those used in biologics, biosimilars, and …

Quoin Pharmaceuticals Releases Q2 2026 Financial Results

Quoin Pharmaceuticals (QNRX) announced its Q2 2026 financial results, reporting a diluted EPS of -$1.90, which is a significant improvement from the -$6.28 loss in Q2 2025. The company posted a net loss of $5.4 million for the quarter. Wall Street analysts currently have …

Insider Selling: Calfrac Well Services (TSE:CFW) Insider Sells 284,000 Shares of Stock

ARK reports 9.59% stake in Pacific Biosciences (PACB)

ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 9.59% in Pacific Biosciences of California, Inc. (PACB), amounting to 29,781,416 shares. This disclosure, made via a SCHEDULE 13G/A filing, details their sole and shared voting and dispositive powers over …

AMR|Alpha Metallurgical Resources Inc|Price:164.337|Chg%:+8.737

This article provides a detailed overview of Alpha Metallurgical Resources Inc (AMR) stock performance, key financial figures, analyst ratings, and company profile. As of the close on August 14, AMR's stock was trading at $166.05, up 6.79%. The company, a mining firm supplying metallurgical …

Alpha Metallurgical Resources Jumps 5.4% After Jefferies Maintains Hold

Alpha Metallurgical Resources (AMR) stock surged 5.4% after Jefferies raised its price target from $150 to $165, while maintaining a "Hold" rating. The analyst's move reflects increased confidence in the coking coal producer's outlook, though it suggests limited upside from current levels. Investors should …

Price-Driven Insight from (CRBP) for Rule-Based Strategy

This article provides a price-driven insight for Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), outlining near-term and mid-term strong sentiment but a weak long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …

Canadian Imperial Bank of Commerce Issues Positive Forecast for Calian Group (TSE:CGY) Stock Price

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

Cal-Maine Foods (CALM) sees American Century, Stowers report 5.3% stake

American Century entities and the Stowers Institute for Medical Research have reported beneficial ownership of over 5% of Cal-Maine Foods' common stock through a Schedule 13G filing. American Century ETF Trust holds 5.1% of common stock, while American Century Investment Management, American Century Companies, …

Kestra Medical Technologies (KMTS) Nears Its Fair Value, Is The Stock Already Fully Valued?

Kestra Medical Technologies (KMTS) has seen recent positive share price momentum, with its stock closing at US$27.74. While a common narrative suggests the stock is undervalued with a fair value of $28 based on ambitious growth assumptions, other metrics like the P/S ratio indicate …

Worker injured in industrial accident at Westlake plant in Calvert City

A contractor's employee was hospitalized after an industrial accident at the Westlake Corporation chemical plant in Calvert City, Kentucky. The worker was injured on a Monday and received immediate care from plant emergency responders before being taken to the hospital. Westlake Corporation has halted …

Namibia Critical Metals Stock Falls 6.82%: Why TSXV:NMI Is in Focus as Lofdal Rare Earths Enters a Critical Development Phase

U.S. Physical Therapy (NYSE:USPH) Trading Down 4.8% - Here's Why

Brandes Investment Partners reports 14.9% Utah Medical Products (UTMD) stake

Brandes Investment Partners has filed an amended Schedule 13G, disclosing a 14.92% passive ownership stake in Utah Medical Products Inc., totaling 475,158 common shares. These shares are held across mutual funds and other accounts advised by Brandes, with the Brandes Small Cap Value Fund …

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day

Eton Pharmaceuticals (ETON) shares surged 40% to an all-time high after better-than-expected Q2 results, driven by the successful relaunch of Hemangeol. The company raised its full-year 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at least 35%. Analysts from B. …

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

Callaway Golf (CALY) Stock May Offer Cash Flow Value As Earnings Look Rich